ABCL (AbCellera Biologics) Cash Flow from Investing: $97.89 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABCL AbCellera Biologics Inc ABCL
50 GF Score
Price $10.90
GF Value $4.35
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbCellera Biologics Cash Flow from Investing?

AbCellera Biologics ABCL +4.16% 50 Cash Flow from Investing is $97.89 Mil as of Jun. 2026. GuruFocus rates ABCL with a GF Score™ of 50/100 and a GF Value™ of $4.35 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2026, AbCellera Biologics spent $2.13 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $141.88 Mil on purchasing investments. It gained $149.76 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $5.59 Mil from other investing activities. In all, AbCellera Biologics gained $11.34 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2026.


AbCellera Biologics  (NAS:ABCL) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

AbCellera Biologics's purchase of property, plant, equipment for the three months ended in Jun. 2026 was $-2.13 Mil. It means AbCellera Biologics spent $2.13 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

AbCellera Biologics's sale of property, plant, equipment for the three months ended in Jun. 2026 was $0.00 Mil. It means AbCellera Biologics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

AbCellera Biologics's purchase of business for the three months ended in Jun. 2026 was $0.00 Mil. It means AbCellera Biologics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

AbCellera Biologics's sale of business for the three months ended in Jun. 2026 was $0.00 Mil. It means AbCellera Biologics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

AbCellera Biologics's purchase of investment for the three months ended in Jun. 2026 was $-141.88 Mil. It means AbCellera Biologics spent {stock_data.stock.currency_symbol}}141.88 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

AbCellera Biologics's sale of investment for the three months ended in Jun. 2026 was $149.76 Mil. It means AbCellera Biologics gained $149.76 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

AbCellera Biologics's net Intangibles purchase and sale for the three months ended in Jun. 2026 was $0.00 Mil. It means AbCellera Biologics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

AbCellera Biologics's cash from discontinued investing activities for the three months ended in Jun. 2026 was 0.00 Mil. It means AbCellera Biologics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

AbCellera Biologics's cash from other investing activities for the three months ended in Jun. 2026 was $5.59 Mil. It means AbCellera Biologics received $5.59 Mil from other investing activities.


AbCellera Biologics Cash Flow from Investing Related Terms


AbCellera Biologics Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Cash Flow from Investing Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial -332.25 -352.63 -221.11 121.41 87.75

AbCellera Biologics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.81 36.49 75.14 -25.08 11.34
ABCL
50GF Score
AbCellera Biologics Inc ABCL
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

AbCellera Biologics's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

AbCellera Biologics's Cash Flow from Investing for the quarter that ended in Jun. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $97.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of $97.89 Mil mean?
AbCellera Biologics (ABCL) has a Cash Flow from Investing of $97.89 Mil as of Jun. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for AbCellera Biologics and its competitors.
Is AbCellera Biologics' Cash Flow from Investing too high?
AbCellera Biologics' current Cash Flow from Investing is $97.89 Mil. Overall, AbCellera Biologics has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Cash Flow from Investing compare to IOVA and RCUS?
AbCellera Biologics' Cash Flow from Investing of $97.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for AbCellera Biologics and its competitors. AbCellera Biologics's current Cash Flow from Investing is $97.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.35, compared to a current price of $10.90 — trading 150.5% above its estimated fair value. The current Cash Flow from Investing is $97.89 Mil. AbCellera Biologics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Cash Flow from Investing is $97.89 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $10.90 is trading 150.5% above its estimated GF Value™ of $4.35. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • Cash Flow from Investing: $97.89 Mil
  • GF Value™: $4.35 vs. price of $10.90 (150.5% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
50GF Score

Get the complete analysis for ABCL

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.90
Price
$4.35
GF Value